Introduction: 

Glaucoma medications are often preserved with agents such as benzalkonium chloride, which commonly lead to ocular surface diseases.
 

Purpose: 

To investigate the effect of switching to a preservative-free prostaglandin analogue, tafluprost 0.0015% on treatment tolerability and ocular surface diseases.
 

Study design: 

This was a prospective, open-label, non-randomised, observational study performed in a single hospital.
 

Materials and methods: 

This study involved patients of Asian descent diagnosed with primary open-angle glaucoma and ocular hypertension (n = 28), who received preserved prostaglandin monotherapy for longer than 3 months and had a National Eye Institute ocular surface staining scale score higher than 1. Patients were switched from preserved prostaglandin monotherapy to preservative-free tafluprost 0.0015%. Patients were analysed at baseline (Visit 0), 1 month (Visit 1), and 3 months (Visit 2). The main parameter measured is the change in the fluorescein staining score at Visit 2.
 

Results: 

There was a significant improvement in the fluorescein staining score, with a mean reduction score of 1.96 (standard deviation, SD = 1.53; p < 0.0001), and significant reductions in conjunctival hyperaemia (bulbar, p < 0.0001; palpebral, p < 0.05) from baseline to Visit 2. The Ocular Surface Disease Index questionnaire also showed a mean reduction of 4.14 from baseline to visit 2 (SD = 8.20; p < 0.05). The intraocular pressure and tear breakup time were maintained from baseline to Visit 2.
 

Conclusion: 

Switching patients to preservative-free tafluprost 0.0015% showed significant improvements in ocular surface disease with minimal side effects and similar intraocular pressure reduction rates.

1. Chan EW, Li X, Tham YC, et al. Glaucoma in Asia: regional prevalence variations and future projections. Br J Ophthalmol. 2016;100(1):78–85.
2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
3. Asia Pacific Glaucoma Society. Asia Pacific Glaucoma Guidelines, 3rd edn. Amsterdam: Kugler Publications; 2016. Available from: https://pdf4pro.com/download/asia-pacific-glaucoma-guidelines-1f2de5.html. Accessed July 2020.
4. Holló G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78(1):39–64.
5. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eye drops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–334.
6. Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2009;4(1):59–64.
7. Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102(11):1497–1503.
8. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.
9. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br J Ophthalmol. 2002;86:418–423.
10. Kuppens EV, de Jong CA, Stolwijk TR, De Keizer RJ, Van Best JA. Effect of timolol with and without preservative on basal tear turnover in glaucoma. Br J Ophthalmol. 1995;79:339–342.
11. Hommer A, Kromus M, Schmidl D, Garhofer G, Schmetterer L. The effect of preservative-free tafluprost on intraocular pressure in ocular hypertension or primary open-angle glaucoma. Int J Ophthalmol Eye Res. 2015;1:27–31.
12. Egorov EA, Astakhov YS, Erichev VP, et al. Evaluation of efficacy and safety of preservative-free tafluprost 0.0015% eye drops in open-angle glaucoma and ocular hypertension. RMJ Clin Ophthalmol. 2015;16:1–6.
13. Pinto LA, Vandewalle E, Gerlier L, Stalmans I, CosoptUD Switch Study Group. Improvement in glaucoma patient quality of life by switching to preservative-free timolol/dorzolamide fixed combination. Ophthalmologica. 2014;231(3):166–171.
14. Hommer A, Kimmich F. Switching patients from preserved prostaglandin analog monotherapy to preservative-free tafluprost. Clin Ophthalmol. 2011;5:623–631.
15. Muñoz-Negrete FJ, Lemij HG, Erb C. Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clin Ophthalmol. 2017;11:557–566.
16. Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–454.
17. Takamura E, Uchio E, Ebihara N, et al. Japanese guideline for allergic conjunctival diseases. Allergol Int. 2011;60:191–203.
18. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118:615–621.
19. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15:539–574.
20. Tumbocon JA, Macasaet AM. Efficacy and safety of tafluprost 0.0015%: retrospective analysis of real-world data from the Philippines. Clin Ophthalmol. 2019;13:1627–1634.
21. Wong TT, Aung T, Ho CL. Ocular surface status in glaucoma patients switched from latanoprost to tafluprost. Clin Exp Ophthalmol. 2018;46:1028–1034.
22. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from preserved to preservative-free prostaglandin therapy in glaucoma. Acta Ophthalmol. 2010;88(3):329–336.
23. Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: evaluation of benzalkonium chloride-free timolol eye drops. Clin Ophthalmol. 2013;7:2131–2135.
24. Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T. Effects of prostaglandin analogues on endothelin-1–induced ocular blood flow impairment. Exp Eye Res. 2010;91(6):853–859.
25. Dong Y, Watabe H, Su G, Ishikawa H, Sato N, Yoshitomi T. Relaxing effect of tafluprost on rabbit ciliary arteries. Exp Eye Res. 2008;87(3):251–256.
26. Shibata M, Sugiyama T, Kojima S, Ueki M, Tomita I. Long-term effects of tafluprost on visual field, morphology, and optic nerve head microcirculation in glaucoma. Jpn J Ophthalmol. 2015;69(5):741–747.